RxDoctor Payments Data

Gabriel Asante-Odame

Psychiatric/Mental Health · Bronx, NYNPI 1275209405

Payments from drug & device makers

$1,934in general payments, 2019–2025

Across 55 payments — averaging $35.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$756
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$472
  • Teva Pharmaceuticals USA, Inc.$305
  • Axsome Therapeutics, Inc.$177
  • Alkermes, Inc.$150
  • Indivior Inc.$35
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$1,934100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,934 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$49,445
Medicare patients
99
Services billed
494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole27$45,744
VraylarCariprazine Hcl18$33,703
CaplytaLumateperone Tosylate16$28,648
Zyprexa ZydisOlanzapine11$11,873
Aripiprazole124$11,620
ZoloftSertraline Hcl18$11,404
AuvelityDextromethorphan Hbr/Bupropion12$8,898
Lurasidone Hcl24$6,882
AbilifyAripiprazole12$6,551
Divalproex Sodium ErDivalproex Sodium92$5,923
VyvanseLisdexamfetamine Dimesylate15$5,844
Clozapine75$4,398
Quetiapine Fumarate281$4,278
Lamotrigine ErLamotrigine12$3,707
Fluphenazine Hcl34$3,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$756$33,70318 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$472$28,64816 claims
Axsome Therapeutics, Inc.Auvelity$177$8,89812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →